Open Access

Markers of neuroprotection of combined EPA and DHA provided by fish oil are higher than those of EPA (Nannochloropsis) and DHA (Schizochytrium) from microalgae oils in Wistar rats

  • Paula A. Lopes1Email author,
  • Narcisa M. Bandarra2, 3,
  • Susana V. Martins1,
  • Joana Martinho1,
  • Cristina M. Alfaia1,
  • Marta S. Madeira1,
  • Carlos Cardoso2, 3,
  • Cláudia Afonso2, 3,
  • Maria C. Paulo4,
  • Rui M. A. Pinto5, 6,
  • José L. Guil-Guerrero7 and
  • José A. M. Prates1Email author
Contributed equally
Nutrition & Metabolism201714:62

https://doi.org/10.1186/s12986-017-0218-y

Received: 11 July 2017

Accepted: 22 September 2017

Published: 29 September 2017

Abstract

Background

To overcome the current overexploitation of fish rich in n-3 long chain polyunsaturated fatty acids (LCPUFA), microalgae have become a promising marine lipid source. The purpose of this study was to assess eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3), isolated or combined from distinct marine origins, on the promotion of neuroprotective effects.

Methods

The experiment lasted for 10 weeks and involved 32 Wistar rats, divided into 4 diets (n = 8): a diet rich in milk fat was taken as control (Milk Fat) and compared to n-3 LCPUFA enriched diets, either in EPA + DHA form through fish oil (Fish Oil), or EPA through Nannochloropsis oil (Nanno), or DHA through Schizochytrium oil (Schyzo), while maintaining Milk Fat incorporation.

Results

Plasma lipid profile and dopamine levels were more beneficial in Fish Oil diet. In addition, n-3 LCPUFA incorporation was found increased in liver and erythrocytes from Fish Oil fed rats, suggesting that fish oil is a better dietary source for fatty acids deposition in the organism than microalgae. The Forced Swimming Test revealed a positive behavioural action of EPA + DHA, in opposition to Milk Fat and Nanno diets, which had higher immobile times. mRNA levels of serotonin receptors, HT1A and HT2A along with CREB, the transmission factor for learning and memory, were higher in the hippocampus of rats fed n-3 LCPUFA diets comparative to Milk Fat.

Conclusion

Taken together, the combination of EPA and DHA from fish oil can counteract the undesirable health effects of saturated fat based diets and benefit, in the long run, neurological function.

Keywords

Fish oil Microalgae Fatty acid composition Forced swimming test Transcriptional profile

Background

Ageing represents the accumulation of changes over time that are associated with or responsible for increased susceptibility to most diseases and death [1]. The European population is getting older and until 2030 the number of seniors aged over 70 is predicted to increase 40%, as will age-related neurodegenerative diseases [2, 3].

The improvement of health of the elderly population through a diet rich in essential nutrients may mitigate the effects of ageing. Precisely, essential nutrients such as n-3 long-chain polyunsaturated fatty acids (n-3 LCPUFA, > 18 C), particularly eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3), are associated to a prophylactic role in certain age-related diseases with particular emphasis to some of the effects of certain degenerative diseases of the nervous system. These FA have a protective role on regulating brain development and neurotransmitter functioning and are recognised as the most beneficial FA in retarding neurological pathologies, such as Alzheimer’s, Parkinson’s and Huntington’s diseases, multiple sclerosis, schizophrenia, cognitive decline and brain ageing, major depression, acute stress and anxiety like behaviours [47]. Their deficiency leads to impaired neuronal function, affecting neurotransmission action [8, 9]. Accordingly, the international nutritional guidelines have recommended the need to increase EPA and DHA intake.

In the human body, DHA is synthesised in limited amounts and, therefore, must be obtained through the diet [10]. Fatty fish is the best source of n-3 LCPUFA [11]. However, due to the excessive and sometimes poorly regulated fishery exploitation, the depletion of worldwide fish stocks is aggravating their sustainability. Thus, search for alternative sources of n-3 LCPUFA to increase their availability and the consumption of these healthy FA is a major demand. Microalgae are a viable option for n-3 LCPUFA production because they do not require arable land for their growth and can operate as biofactories using only sunlight energy, thereby having the ability to accumulate high levels of FA under adverse environmental conditions [12]. In fact, new improvements on microalgae production have been made concerning growth optimization requirements, able to produce highly pure EPA and DHA oils [13] containing up to 30–40% of a target FA [14]. Some microalgae oils have also demonstrated safety nutritional profiles with no trace of toxicity, because they are produced under controlled conditions, thus being approved for consumption by the Food and Drug Administration.

Despite the body of evidence on n-3 LCPUFA positive effects on retarding and treating the neurologic conditions stated above [15, 16], a key question remains to be answered [17, 18]: are the benefits ascribed to EPA and DHA individual action or a result from the combination of both fatty acids (EPA + DHA)?

In this study, the impact of microalgae oils rich in EPA and DHA, as alternative marine lipid sources to fish oils was assessed on the neurological function of Wistar rats. We hypothesised that blue biotechnology can efficiently provide n-3 LCPUFA to counteract the undesirable health effects of saturated fat based diets by means of improving the biochemical profile, changing FA composition of key tissues, preventing inflammatory processes, enhancing neurological function, and modifying rat’s behaviour. To establish the effects of EPA and DHA, isolated or combined, on the promotion of neuroprotective effects, fish oil was used for comparative purposes.

Methods

Experimental diets

Diets were manufactured by the Experimental Diets Unit from the University of Almería, Spain. The proximate chemical composition of the diets was determined according to AOAC [19], and FA composition was assessed as described by Bandarra et al. [20]. All diets were based on the standard AIN-93 M formulation for rodents with modified lipid fractions, as follows: milk fat diet (Milk Fat group), a negative control with 20% of fat (12% from milk and 8% from soybean oil); milk fat diet plus cod liver oil (Fish Oil group), a positive control with 20% of fat (12% from milk, 4% from soybean oil and 4% from cod liver oil which is rich in EPA and DHA); milk fat diet plus Nannochloropsis microalga oil (Nanno group) with 20% of fat (12.5% from milk fat, 5.9% from soybean oil and 2.4% from Nanno oil which is rich in EPA); milk fat diet plus Schizochytrium microalga oil (Schyzo group) with 20% of fat (12.2% from milk fat, 6.5% from soybean oil and 1.8% from Schyzo oil which is rich in DHA) (Table 1). Nannochloropsis was purchased at Monzón BIOTECH, S.L. (Barcelona, Spain) and Schizochytrium was produced by Instituto Português do Mar e da Atmosfera (IPMA, Lisboa, Portugal), according to conditions outlined in previous studies [21].
Table 1

Ingredients, chemical composition and fatty acid profile of Milk Fat, Fish Oil, Nanno and Schyzo experimental diets

 

Milk Fat

Fish Oil

Nanno

Schyzo

Ingredients (%)

 Casein

14.0

14.0

10.8

12.5

 Corn starch

37.8

37.8

39.2

38.4

 Maltodextrin

7.0

7.0

7.3

7.1

 Sucrose

10.0

10.0

10.4

10.1

 Cellulose

5.0

5.0

5.2

5.1

 Soybean oil

8.0

4.0

5.9

6.5

 Milk fat

12.0

12.0

12.5

12.2

 Fish oil

0

4.0

0

0

 Nanno oil

0

0

2.4

0

 Schyzo oil

0

0

0

1.8

 Cholesterol

1.25

1.25

1.30

1.27

 L-cysteine

0.20

0.20

0.20

0.20

 Mineral AIN-93 M Mix

3.50

3.50

3.60

3.60

 Vitamin AIN-93 M Mix

1.00

1.00

1.00

1.00

 Choline bitartarate

0.20

0.20

0.30

0.30

 TBHQ (antioxidant)

0.001

0.001

0.001

0.001

Chemical composition (g/100 g)

 Crude protein

12.3

12.1

14.7

12.6

 Crude fat

19.2

20.2

17.0

21.6

 Crude fibre

3.80

3.80

3.80

3.80

 Moisture

5.60

5.60

5.60

5.60

 Crude ash

3.57

3.50

3.82

3.60

 Carbohydrates

55.6

54.8

55.0

52.9

 Total FAME (mg/g)

220

202

236

185

 Energy (kcal/100 g)

444

449

432

456

Fatty acid profile (%)

 14:0

9.81

11.1

10.0

9.32

 16:0

28.5

28.8

28.9

29.0

 18:0

6.95

6.87

6.32

6.67

 18:1n-9

20.3

19.1

18.0

17.0

 18:2n-6

21.2

12.3

15.7

16.3

 18:3n-3

2.56

1.59

1.88

2.04

 18:4n-3

0.190

0.410

0.189

0.187

 20:4n-6

0.086

0.138

0.587

0.110

 20:5n-3

ND

1.15

3.16

0.10

 22:6n-3

ND

1.19

ND

3.30

Partial sums and ratios

 Total SFA

51.1

52.9

51.2

52.1

 Total MUFA

22.0

26.6

23.8

20.4

 Total PUFA

24.3

17.8

21.9

23.7

 Total n-3

2.75

4.64

5.23

5.72

 Total n-6

21.4

12.7

16.4

17.8

n-3/n-6

0.129

0.366

0.320

0.321

TBHQ tertiary butyl hydroquinone, ND not detected

Animals and sample collection

A total of thirty-two male Wistar rats (Harlan Interfauna Iberica SL, Barcelona, Spain), aged 28 d, were housed individually under a 12 h light-12 h dark cycle and at a temperature of 22–25 °C. After an adaptation period of 1 week to minimise stress and stabilize all metabolic conditions, rats were assigned to four body weight-matched groups with eight animals each: Milk Fat, Fish Oil, Nanno and Schyzo. Body weight and feed intake were recorded twice a week. Faeces were collected and stored at −80 °C in vacuum bags for further FA analysis. At the end of 10 weeks, rats were fasted for 12 h and killed by decapitation, under light isoflurane anaesthesia. The trunk blood was collected in lithium heparin tubes and was left to stand for 30 min. Plasma was obtained after centrifugation at 1500 g for 10 min. Erythrocytes were obtained after washing the pellet twice with 0·9% sodium chloride and centrifuging at 1500 g for 15 min and the correspondent aliquots were flash-frozen in liquid N2 and stored at −80 °C, for further analysis. Liver, brain and hippocampus were removed, weighed and stored at −80 °C for FA determination. Samples for gene (serotonin 5-HT1A receptor (HT1A), serotonin 5-HT2A receptor (HT2A), brain-derived neurotrophic factor (BDNF), cAMP responsive element binding protein (CREB), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) expression analysis were collected from the hippocampus, rinsed with sterile RNAse-free cold saline solution, cut into small pieces (thickness of ~0.3 cm), stabilised in RNA Later® solution (Qiagen, Hilden, Germany) and stored at −80 °C.

Plasma biochemical assays

The plasma concentrations of total cholesterol, HDL-cholesterol, LDL-cholesterol, triacylglycerols (TAG), glucose, creatinine, urea, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and gamma glutamyl transferase (γ-GT) were determined using standard diagnostic test kits obtained from Roche Diagnostics (Mannheim, Germany) in the Modular Hitachi Analytical System (Roche Diagnostics). The concentrations of VLDL-cholesterol and total lipids were calculated according to the Friedewald et al. [22] and Covaci et al. [23] formulas, respectively.

TNF-α and IL-6 were measured simultaneously, in duplicate, using Millipore’s MILLIPLEX rat cytokine panel (Millipore, Billerica, MA, USA). The assays were conducted according to the manufacturer’s instructions. The plate was run on a Luminex 200 Instrument using Bio-Plex Manager 4.1 standard software (Bio-Rad Laboratories, Hercules, CA, USA). Raw fluorescence data were analysed by software using a 5-parameter logistic method. The minimum detection concentrations were 2.4 pg/ml and 73.2 pg/ml for TNF-α and IL-6, respectively. The intra- and inter-assay precision of the cytokine panel were 2.3–3.6% and 11.3–14.3%, respectively.

Fatty acid composition in faeces, liver, erythrocytes and brain

After lipid extraction by the Bligh and Dyer method [24], fatty acid methyl esters (FAME) were determined in the extracted lipids from faeces, liver, erythrocytes and brain by acid-catalysed transesterification using the methodology described by Bandarra et al. [25]. Samples were injected into a Varian Star 3800 CP gas chromatograph (Walnut Creek, CA, USA), equipped with an auto sampler with a flame ionisation detector (FID) at 250 °C. FAME were identified by comparing their retention times with those of standards (PUFA-3, Menhaden oil, and PUFA-1, Marine Source from Supelco Analytical, Sigma-Aldrich, St. Louis, MO, USA). The quantification of total FA was based on the internal standard technique, using the heneicosanoic acid (21:0) (Sigma-Aldrich). Results for each FA were expressed as a percentage of the sum of detected FA (% total FA).

Lipid class analysis in brain

The main lipid classes were separated by analytical thin-layer chromatography (TLC) in plates coated with 0.25 mm silica gel G and developed with a mixture of chloroform:methanol:water (56:41:3 by volume), based on Bandarra et al. [25]. The developed plates were sprayed with 10% of phosphomolybdic acid in ethanol (w/v). The identification of lipid classes (polar and non-polar) was performed by comparison with standards (Sigma Chemical Co., St. Louis, MO, USA) and the quantification using a scanner and Quantity One 1-D Analysis software (version 4.5.2, Bio-Rad) [25].

Behavioural analysis: Forced swimming test

The behavioural effects of n-3 LCPUFA were tested one week prior to euthanasia using the blinded Forced Swimming Test (FST), according to Porsolt et al. [26] with slight modifications. The identification of rats was ensured by a code in order to avoid bias. Each rat was put individually into vertical cylinders (60 cm height and 20 cm diameter) containing water at 25 °C (± 2 °C) with 30 cm deep for a 15 min pre-test. The cylinders were made of transparent Plexiglas as this material is able to withstand the frequent movement of the tanks and accidents better than glass. Water volume prevented the animal from escaping or touching the bottom of the cylinder. Behavioural tests were done individually, one at a time, to prevent copying and avoid bias. The room was under control to guarantee that noises, light changing or reflexes would not affect rat’s behaviour. At the end of the pre-test, the animal was taken from the water, dried with a towel to prevent hypothermia and then put back into its cage, so it could rapidly resettle to its normal conditions. The water was changed after each experiment to remove urine, faeces and odour clues left by the previous rat and thus, to avoid interferences on the next rat. 24 h later, the rat was exposed to the same aforementioned experimental conditions for a 5 min FST. This final test was recorded by a conventional video camera positioned in front of the Plexiglas cylinder. Behavioural times were calculated with proper software [27] (Ethowatcher®) and classified from most active to least active, as climbing (active upward movement), swimming (active lateral movement), floating (passive fluctuating movement) and immobile (absence of movement).

Determination of serotonin and catecholamines

Plasma 5-hydroxytryptamine (5-HT, serotonin) and catecholamines were determined by high-performance liquid chromatography – electrochemical detection method (HPLC-ECD).

Serotonin was determined using a ClinRep kit for “serotonin in plasma/serum” (Recipe Chemicals + Instruments GmbH, Munich, Germany). Briefly, 200 μl of plasma containing N-methylserotonin as an internal standard (10 μl) was precipitated to remove proteins and lipids. The supernatant was separated on a Shimadzu series 10 HPLC system by a reversed-phase column and using an isocratic mobile phase (ClinRep, ref.: 6710) equipped with a Shimadzu series 6 electrochemical detector. The conditions for obtaining the chromatograms were as follows: a) temperature: 30 °C; b) detector: potential - 0.45 V; c) flow: 1.0 ml/min. Data obtained from the HPLC system were treated using software suitable for this type of assays (Shimadzu class 10-A software). Quality control of the system was accomplished by running ClinRep controls in two levels. The day-to-day CV was 5.4% and 5.3%, respectively. The lower limit of quantitation (LLOQ) was 1 μg/l. Catecholamines were determined using a Bio-Rad kit for “Plasma catecholamines by HPLC” (Bio-Rad, Madrid, Spain). Briefly, 50 μl of plasma containing dihydroxybenzylamine as an internal standard (5 μl) was treated with alumina (extraction phase). HPLC analysis of the supernatant was performed with an analytical cation exchange column specific for catecholamines PCAT (Bio-Rad, ref.: 195–6079) and an isocratic mobile phase purchased from Bio-Rad (ref: 195–6056). Catecholamines determinations were performed on a Shimadzu series 10 HPLC system equipped with a Shimadzu series 6 electrochemical detector. The conditions for obtaining the chromatograms were as follows: a) temperature: 30 °C; b) detector: potential - 0.50 V; c) flow: 1.1 ml/min. Data obtained from the HPLC system were treated using software suitable for this type of assays (Shimadzu class 10-A software). In each series of determinations, control samples (Lyphochek, Bio-Rad, ref. 530) were analysed in order to monitor the quality of each of the assays performed. The day-to-day CV was 4.9%. The lower limit of quantitation (LLOQ) was 25 pg/ml.

Hippocampus RNA extraction and cDNA synthesis

Total RNA was extracted from hippocampus using the RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden, Germany). To exclude possible existing genomic DNA, on-column DNase digestion with the RNase-Free DNase set (Qiagen) was performed. All procedures were based on the manufacturer’s protocol. RNA quality and concentration were determined by spectrophotometry at A260 and by the A260/A280 ratio using a NanoDrop® ND-2000c, respectively (Thermo Scientific, Wilmigton, DE, USA). To generate cDNA for qPCR, 300 ng of total RNA were reverse transcribed for 2 h at 37 °C using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA).

Real time quantitative PCR (RT-qPCR)

mRNA expression levels were quantified using the SYBR green technology and MicroAmp Optical 96-well plates in a StepOnePlus thermocycler at standard cycling conditions (Applied Biosystems). Gene specific intron-spanning primers were designed using Primer Express® Software v.3.0 (Applied Biosystems) based on Rattus norvegicus sequences (www.ncbi.nlm.nih.gov). Specific sense and antisense primers used to amplify cDNA were purchased from NZYTech (Lisbon, Portugal). The specific primers were: HT1A (5′-GATCTCGCTCACTTGGCTCA-3′ and 5′-AGCGCCGAAAGTGGAGTAGA-3′); HT2A (5′-CACCACAGCCGCTTCAACTC-3′ and 5′-CACCACAGCCGCTTCAACTC-3′); BDNF (5′-AGGGATCCACACTGCCACTG-3′ and 5′-GAATTCCTCCTGCTCTGCCAG-3′); CREB (5′-CCTCCCCAGCACTTCCTACA-3′ and 5′-TCAAGCACTGCCACTCTGTTC-3′); TNF-α (5′-TCTTCTCATTCCTGCTCGTGG-3′ and 5′-GTCTGGGCCATGGAACTGAT-3′); IL-6 (5′-GGATACCACCCACAACAGACC-3′ and 5′-AGTGCATCATCGCTGTTCATACA-3′); glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (5′-CAGTGCCAGCCTCGTCTCAT-3′ and 5′-CACAAGAGAAGGCAGCCCTG-3′); and ribosomal protein L27 (RPL27) (5′-GCCATGGGCAAGAAGAAGATC-3′ and 5′-GCTGGGTCTCTGAACACATCCT-3′). PCR efficiency was calculated for each amplicon using the StepOnePlus PCR System software, by amplifying 5-fold serial dilutions of pooled cDNA and running in triplicate. All primer sets were required to exhibit similar amplification efficiencies. The primer specificity and formation of primer-dimers were checked by melt curve analysis. A set of four candidate housekeeping genes was evaluated using geNorm and NormFinder, as described by Vandesompele et al. [28] and Andersen et al. [29], respectively. GADPH and RPL27 genes were selected as the most stable pair of internal controls for normalization. All analyses were performed in duplicate, and the relative amounts for each target gene were calculated using the geometric mean of housekeeping genes as normalizer. Relative expression levels were calculated as a variation of the Livak method [30] corrected for variation in amplification efficiency, as described by Fleige and Pfaffl [31].

Statistical analysis

Statistical analysis was carried out using the Statistical Analysis System (SAS) software package, version 9.1 (SAS Institute, USA). Sample size was determined by the POWER procedure of SAS. A sample size of 8 rats provided a statistical power of at least 80% for detecting 20% differences with a 2-tailed probability of P < 0.05. All data were checked for normal distribution and variance homogeneity and reported as means ± standard error (SE). Data were analysed using PROC MIXED to accommodate variance heterogeneity. If significant effects were obtained, least squares means were determined using the LSMEANS option and compared using the probability difference procedure (PDIFF adjust Tukey). The PROC CORR method was used to obtain Pearson’s correlation coefficients between n-3/n-6 PUFA ratio in erythrocvtes and other parameters. P-values lower than 0.05 were considered statistically significant.

Results

Animal body composition

Body composition parameters of rats fed different n-3 LCPUFA sources are shown in Table 2. Most of the variables presented no changes across dietary groups, except total body weight gain that was found increased in Milk Fat in comparison to Schyzo (P < 0.05). Rats fed Nanno diet had higher values of daily feed intake than Fish Oil and Schyzo (P < 0.05). Carcass weight was found increased in Nanno relative to Schyzo (P < 0.05).
Table 2

Body composition parameters and plasma metabolites

 

Milk Fat

Fish Oil

Nanno

Schyzo

Significance

Mean

SE

Mean

SE

Mean

SE

Mean

SE

 

Growth parameters and tissues weight (g)

 Final body weight

460

10.7

449

13.1

460

10.4

426

9.04

0.062

 Total body weight gain

159a

6.59

148ab

7.18

152ab

6.05

129b

6.39

0.020

 Daily feed intake

21.0ab

0.331

19.6c

0.330

21.8a

0.348

19.7bc

0.487

0.001

 Liver

13.6

0.687

13.3

0.573

13.8

0.553

13.8

0.485

0.931

 Brain

1.48

0.035

1.46

0.031

1.42

0.030

1.45

0.022

0.588

 Hippocampus

0.392

0.012

0.433

0.025

0.401

0.014

0.414

0.031

0.533

Longissimus dorsi muscle

6.26

0.339

6.71

0.406

6.54

0.275

6.66

0.321

0.809

 Epididymal fat

6.01

0.646

5.59

0.510

6.20

0.459

5.21

0.308

0.315

 Retroperitoneal fat

4.62

0.654

4.05

0.405

4.63

0.320

4.54

0.413

0.712

 Carcass

199ab

3.73

195ab

5.23

201a

3.44

185b

4.52

0.046

Biochemistry profile

 Total cholesterol (mg/dl)

67.3a

1.16

50.4c

1.35

54.5c

1.02

61.9b

1.41

< 0.001

 HDL-Cholesterol (mg/l)

13.6

0.498

12.4

0.905

12.4

0.565

13.4

0.596

0.327

 LDL-Cholesterol (mg/dl)

32.2b

0.631

24.0d

0.949

28.5c

0.745

35.3a

0.686

< 0.001

 VLDL-Cholesterol (mg/dl)†

21.8a

0.235

14.0b

0.305

13.6b

0.371

13.2b

0.236

< 0.001

 LDL-C/HDL-C

2.33b

0.045

2.01b

0.143

2.34ab

0.111

2.66a

0.068

< 0.001

 Triacylglycerols (mg/dl)

109a

1.18

70.0b

1.52

68.1b

1.86

66.0b

1.18

< 0.001

 Total lipids (mg/dl)‡

395a

2.75

320c

1.03

327bc

2.99

340b

3.66

< 0.001

 Glucose (mg/dl)

174a

2.15

150b

2.04

136c

2.83

129c

3.29

< 0.001

 Creatinine (mg/dl)

0.258

0.008

0.255

0.009

0.248

0.009

0.281

0.012

0.187

 Urea (mg/dl)

28.5c

1.02

33.8b

1.08

32.3bc

1.31

41.5a

1.21

< 0.001

 Total proteins (g/dl)

6.83

0.067

6.66

0.110

6.84

0.065

6.61

0.064

0.061

Hepatic and inflammatory markers

 AST (U/l)

112c

4.93

141b

5.26

81.3d

2.25

184a

7.08

< 0.001

 ALT (U/l)

44.3a

2.40

50.6a

1.28

36.4b

1.49

50.5a

3.02

< 0.001

 ALP (U/l)

94.6b

1.99

130a

6.58

85.9c

1.83

78.8d

2.47

< 0.001

 γ-GT (U/l)

2.10a

0.118

2.19a

0.096

0.440c

0.113

1.10b

0.085

< 0.001

 TNF-α (pg/ml)

155

11.6

168

24.7

124

6.86

141

9.88

0.080

 IL-6 (pg/ml)

4219b

456

4420b

333

3772b

463

7760a

237

< 0.001

n = 8 per group. a,b,c Means in the same row with different superscripts are significantly different (PDIFF adjust Tukey, P < 0.05). †VLDL-Cholesterol = 1/5 [triacylglycerols]. ‡Total lipids = [total cholesterol] × 1.12 + [triacylglycerols] × 1.33 + 148

Plasma metabolites and inflammatory status

Biochemistry profile, markers of hepatic and renal function, and inflammation are also shown in Table 2. Total cholesterol, VLDL-cholesterol, TAG, total lipids and glucose were higher in Milk Fat group in comparison to the others (P < 0.001). Rats fed Schyzo diet had increased levels of LDL-cholesterol than the others (P < 0.001). LDL-C/HDL-C ratio was also higher in Schyzo group relative to Milk Fat and Fish Oil (P < 0.001). Although creatinine remained unchanged across dietary groups (P > 0.05), urea was found higher in Schyzo (P < 0.001). Regarding the hepatic markers, AST was increased in Schyzo and decreased in Nanno (P < 0.001). ALT and γ-GT were reduced in Nanno (P < 0.001) whereas ALP was reduced in Schyzo (P < 0.001). TNF-α presented no variations across dietary groups (P > 0.05), but IL-6 was increased in Schyzo fed rats (P < 0.001).

Fatty acid composition in faeces, liver and erythrocytes

FA composition in faeces is shown in Table 3. The fatty acid content was higher in Fish Oil and lower in Nanno (P < 0.001). Except for SFA, rats fed Nanno had increased excretion levels for MUFA (P < 0.001) (due to 16:1n-9n-7, 17:1 and 18:1n-9 (oleic acid, OA) variations), PUFA, n-3 PUFA (P < 0.001) (due to 18:3n-3 (α-linolenic acid, ALA) and EPA variations) and n-6 PUFA (P < 0.001) (due to 18:2n-6 (linoleic acid, LA) and 20:4n-6 (arachidonic acid, AA) variations). DHA was undetected in faeces.
Table 3

Total FAME (mg/g) and fatty acid composition (% total fatty acids) in faeces

 

Milk Fat

Fish Oil

Nanno

Schyzo

Significance

Mean

SE

Mean

SE

Mean

SE

Mean

SE

 

Total FAME

111ab

17.2

126a

9.72

64.2b

4.04

108a

11.1

< 0.001

Fatty acids

 11:0

0.300b

0.064

0.540a

0.043

0.750a

0.074

0.330b

0.018

< 0.001

 13:0

0.150b

0.100

0.050b

0.002

0.670a

0.042

0.060b

0.007

< 0.001

 14:0isobr

0.060b

0.009

0.050b

0.004

0.320a

0.026

0.040b

0.006

< 0.001

 14:0

3.93b

0.492

6.05a

0.277

5.95a

0.361

4.80b

0.201

< 0.001

 15:0isobr

0.260b

0.036

0.260b

0.025

1.17a

0.045

0.250b

0.011

< 0.001

 15:0anteiso

0.406

0.054

0.370

0.032

0.462

0.030

0.455

0.026

0.161

 15:0

1.35bc

0.090

1.56b

0.089

1.17c

0.086

3.71a

0.112

< 0.001

 16:0anteiso

0.140bc

0.018

0.100c

0.009

0.450a

0.077

0.150b

0.008

< 0.001

 16:0

44.2b

1.64

46.7b

0.528

38.7c

0.804

51.7a

0.806

< 0.001

 16:1n-9n-7

0.090d

0.013

0.330b

0.029

7.20a

0.418

0.170c

0.016

< 0.001

 17:0isobr

0.282

0.010

0.293

0.038

0.265

0.004

0.258

0.005

0.198

 17:0

0.790b

0.020

0.820b

0.014

0.640c

0.017

1.61a

0.016

< 0.001

 17:1

0.200bc

0.017

0.220b

0.015

0.420a

0.018

0.150c

0.014

< 0.001

 16:4n-3

0.067

0.010

0.062

0.006

0.058

0.013

ND

0.847

 18:0

29.0a

1.50

24.5b

0.629

15.6d

0.579

21.5c

0.530

< 0.001

 18:1n-9

4.89a

0.433

4.55a

0.248

4.80a

0.261

3.78b

0.136

0.002

 18:1n-7

3.48a

0.335

2.86a

0.234

1.24b

0.164

2.60a

0.234

< 0.001

 18:1n-5

1.20a

0.137

1.05a

0.070

0.630b

0.018

1.20a

0.124

< 0.001

 19:0isobr

0.410a

0.045

0.240b

0.017

0.140c

0.006

0.210b

0.019

< 0.001

 18:2n-6

1.93b

0.334

1.33b

0.060

3.16a

0.203

1.67b

0.078

< 0.001

 19:0

0.140b

0.013

0.130b

0.003

0.180a

0.005

0.180a

0.004

< 0.001

 18:3n-3

0.210a

0.023

0.070c

0.008

0.240a

0.021

0.120b

0.015

< 0.001

 18:4n-3

0.161

0.036

0.172

0.032

0.115

0.036

0.136

0.019

0.620

 20:0

1.41a

0.156

1.13a

0.093

0.790b

0.040

0.710b

0.039

< 0.001

 20:1n-7

0.300ab

0.100

0.430a

0.037

0.110b

0.026

0.250b

0.049

< 0.001

 20:2n-6

0.210ab

0.037

0.240a

0.014

0.110b

0.028

0.320a

0.039

< 0.001

 20:4n-6

0.110bc

0.042

0.070c

0.009

0.820a

0.057

0.190b

0.023

< 0.001

 20:5n-3

ND

0.080b

0.012

5.45a

0.439

ND

< 0.001

 22:0

0.870a

0.114

0.640a

0.048

0.300b

0.034

0.400b

0.029

< 0.001

 22:5n-3

0.570a

0.117

0.370ab

0.052

0.270b

0.014

0.510ab

0.114

0.014

 Others

2.88b

0.270

4.73b

0.191

7.82a

0.301

2.54b

0.410

< 0.001

Partial sums and ratios

 Total SFA

83.7ab

1.31

83.4b

0.784

67.6c

1.38

86.4a

0.716

< 0.001

 Total MUFA

10.2bc

0.821

9.44b

0.625

14.4a

0.654

8.15c

0.290

< 0.001

 Total PUFA

3.26b

0.433

2.39b

0.126

10.2a

0.741

2.95b

0.172

< 0.001

 Total n-3

1.01b

0.156

0.754b

0.103

6.13a

0.499

0.766b

0.125

< 0.001

 Total n-6

2.25bc

0.393

1.64c

0.072

4.09a

0.258

2.18b

0.098

< 0.001

n-3/n-6

0.448ab

0.505

0.460b

0.075

1.50a

0.055

0.351b

0.055

< 0.001

n = 8 per group. ND, not detected. Total SFA = 11:0 + 13:0 + 14:0isobr + 14:0 + 15:0isobr + 15:0anteiso + 15:0 + 16:0anteiso + 16:0 + 17:0isobr + 17:0 + 18:0 + 19:0isobr + 19:0 + 20:0 + 22:0; Total MUFA = 16:1n-9n-7 + 17:1 + 18:1n-9 + 18:1n-7 + 18:1n-5 + 20:1n-7; Total PUFA = 16:4n-3 + 18:2n-6 + 18:3n-3 + 18:4n-3 + 20:2n-6 + 20:4n-6 + 20:5n-3 + 22:5n-3; Total n-3 = 16:4n-3 + 18:3n-3 + 18:4n-3 + 20:5n-3 + 22:5n-3; Total n-6 = 18:2n-6 + 20:2n-6 + 20:4n-6. a,b,c Means in the same row with different superscripts are statistically different (PDIFF adjust Tukey, P < 0.05)

FA composition in liver is presented in Table 4. The fatty acid content was lower in Schyzo when compared to Nanno (P = 0.009). SFA sum was decreased in Milk Fat fed rats relative to the others (P < 0.001), due to 15:0 (P < 0.001), 16:0 (P < 0.001), 17:0 (P < 0.001) and 18:0 (stearic acid, SA) (P = 0.003) variations. Rats fed Fish Oil had higher levels of total MUFA, in particular of 16:1n-9 (P = 0.008), 16:1n-7 (P < 0.001), OA (P < 0.001) and 20:1n-9 (P < 0.001) than Milk Fat and Schyzo (P < 0.001), but identical to Nanno. PUFA and n-6 PUFA were increased in Milk Fat fed rats (P < 0.001) in comparison to the others due to LA, 20:2n-6 and AA (P < 0.001) variations. n-3 sum and n-3/n-6 ratio were increased in Fish Oil relative to Milk Fat and Nanno (P < 0.001) due to changes in 20:4n-3, EPA and DHA (P < 0.001). While EPA reached higher values in Fish Oil and Nanno (P < 0.001), DHA reached higher values in Fish Oil and Schyzo (P < 0.001).
Table 4

Total FAME (mg/g) and fatty acid composition (% total fatty acids) in liver

 

Milk Fat

Fish Oil

Nanno

Schyzo

Significance

Mean

SE

Mean

SE

Mean

SE

Mean

SE

 

Total FAME

317ab

9.38

324ab

13.7

340a

16.5

308b

9.09

0.009

Fatty acids

 12:0

0.103a

0.005

0.089a

0.007

0.129a

0.015

0.064b

0.005

< 0.001

 14:0

1.67b

0.077

1.91ab

0.128

2.33a

0.137

1.19c

0.081

< 0.001

 15:0

0.391c

0.009

0.525b

0.017

0.596b

0.025

1.05a

0.053

< 0.001

 16:0

18.1b

0.186

24.2a

0.484

24.4a

0.510

24.3a

1.08

< 0.001

 16:1n-9

0.416b

0.033

0.622a

0.055

0.421b

0.031

0.392b

0.026

0.008

 16:1n-7

2.13b

0.220

3.40a

0.402

4.58a

0.471

1.74b

0.151

< 0.001

 17:0isobr

0.274b

0.005

0.365a

0.019

0.357a

0.014

0.292ab

0.029

<0.001

 17:0

0.221d

0.008

0.270c

0.015

0.346b

0.019

0.541a

0.025

<0.001

 16:3n-4

0.212b

0.009

0.293a

0.020

0.322a

0.020

0.261ab

0.017

<0.001

 17:1

0.089

0.005

0.109

0.008

0.098

0.007

0.104

0.015

0.192

 18:0

6.10b

0.369

6.62ab

0.587

7.47ab

0.652

8.19a

0.359

0.003

 18:1n-9

21.7b

0.289

24.9a

0.595

21.2b

0.329

19.2c

0.578

< 0.001

 18:1n-7

2.00a

0.070

2.21a

0.060

2.25a

0.077

1.68b

0.056

< 0.001

 19:0isobr

0.186b

0.006

0.227a

0.012

0.253a

0.016

0.157b

0.009

< 0.001

 18:2n-6

30.7a

0.471

18.3c

0.325

21.6b

0.417

21.1b

0.259

< 0.001

 19:0

0.412a

0.025

0.113d

0.005

0.167b

0.006

0.141c

0.002

< 0.001

 18:3n-3

2.57a

0.293

1.33b

0.086

1.50b

0.097

1.38b

0.055

0.003

 18:4n-3

0.145

0.025

0.114

0.012

0.083

0.021

0.093

0.025

0.269

 20:1n-9

0.222b

0.008

0.574a

0.029

0.097c

0.003

0.071d

0.005

< 0.001

 20:1n-7

0.103

0.014

0.121

0.018

0.099

0.007

0.099

0.012

0.688

 20:2n-6

0.344a

0.021

0.126b

0.003

0.135b

0.004

0.100c

0.006

< 0.001

 20:4n-6

5.88a

0.257

2.51b

0.308

4.37ab

0.254

5.40ab

0.324

< 0.001

 20:4n-3

0.180ab

0.060

0.272a

0.033

0.117b

0.013

0.103b

0.014

< 0.001

 20:5n-3

0.513c

0.075

2.17a

0.217

2.08a

0.209

0.900b

0.093

< 0.001

 22:4n-6

0.242a

0.014

0.053b

0.003

0.091b

0.005

0.100ab

0.017

< 0.001

 22:5n-3

0.715b

0.081

1.18a

0.070

1.31a

0.112

0.409b

0.081

< 0.001

 22:6n-3

1.33b

0.067

3.85a

0.293

0.598c

0.051

6.43a

1.18

< 0.001

 Others

3.04ab

0.089

3.40b

0.120

3.05a

0.057

4.53c

0.265

< 0.001

Partial sums and ratios

 Total SFA

27.4b

0.288

34.4a

0.846

36.1a

0.980

35.9a

1.55

< 0.001

 Total MUFA

26.7b

0.492

32.0a

0.955

28.7ab

0.780

23.3c

0.756

< 0.001

 Total PUFA

42.8a

0.378

30.2c

1.04

32.1bc

0.885

36.3b

1.83

< 0.001

 Total n-3

5.45b

0.505

8.92a

0.599

5.69b

0.430

9.31a

1.36

< 0.001

 Total n-6

37.2a

0.604

21.0c

0.555

26.1b

0.544

26.7b

0.554

< 0.001

n-3/n-6

0.148c

0.017

0.423a

0.022

0.217b

0.013

0.343ab

0.044

< 0.001

n = 8 per group. Total SFA = 12:0 + 14:0 + 15:0 + 16:0 + 17:0isobr + 17:0 + 18:0 + 19:0isobr + 19:0; Total MUFA = 16:1n-9 + 16:1n-7 + 18:1n-9 + 18:1n-7 + 20:1n-9 + 20:1n-7; Total PUFA = 16:3n-4 + 18:2n-6 + 18:3n-3 + 18:4n-3 + 20:2n-6 + 20:4n-6 + 20:4n-3 + 20:5n-3 + 22:4n-6 + 22:5n-3 + 22:6n-3; Total n-3 = 18:3n-3 + 18:4n-3 + 20:4n-3 + 20:5n-3 + 22:5n-3 + 22:6n-3; Total n-6 = 18:2n-6 + 20:2n-6 + 20:4n-6 + 22:4n-6. a,b,c Means in the same row with different superscripts are statistically different (PDIFF adjust Tukey, P < 0.05)

FA composition in erythrocytes is shown in Table 5. It exhibited several resemblances to liver’s, in particular for MUFA (P < 0.001), n-3 PUFA (P < 0.001) and n-3/n-6 ratio (P < 0.001). The same applies for EPA (P < 0.001) and DHA (P < 0.001). The n-6 PUFA reached the highest value in Milk Fat fed rats in comparison to the others (P < 0.001), due to variations in LA (P < 0.001), 20:2n-6 (P < 0.001), AA (P < 0.001) and 22:4n-6 (P < 0.001). The SFA sum was similar across diets (P > 0.05), although small changes were observed for 15:0, 17:0, 18:0, 19:0, 20:0 and 22:0 (P < 0.001).
Table 5

Total FAME (mg/g) and fatty acid composition (% total fatty acids) in erythrocytes

 

Milk Fat

Fish Oil

Nanno

Schyzo

Significance

Mean

SE

Mean

SE

Mean

SE

Mean

SE

 

Total FAME

9.82

0.718

10.6

0.455

10.8

0.320

11.7

0.889

0.521

Fatty acids

 14:0

0.550

0.052

0.680

0.044

0.730

0.037

0.780

0.170

0.068

 15:0

0.360a

0.024

0.430a

0.027

0.450b

0.011

0.940

0.066

< 0.001

 16:0anteiso

2.34

0.071

2.31

0.062

2.61

0.094

2.24

0.111

0.050

 16:0

23.9

1.18

25.7

1.09

26.0

0.459

24.8

0.942

0.329

 16:1n-9

0.120b

0.017

0.190a

0.007

0.160b

0.005

0.160ab

0.012

0.005

 16:1n-7

0.320c

0.033

0.520ab

0.035

0.720a

0.068

0.420bc

0.040

< 0.001

 17:0isobr

0.260c

0.006

0.270c

0.007

0.300b

0.004

0.330a

0.005

< 0.001

 17:0

0.460c

0.010

0.440c

0.010

0.580b

0.007

0.760a

0.009

< 0.001

 16:3n-4

0.300b

0.022

0.320ab

0.029

0.350ab

0.030

0.390a

0.016

0.009

 17:1

0.230a

0.012

0.210a

0.012

0.190a

0.015

0.150b

0.008

< 0.001

 16:3n-3

2.44

0.066

2.42

0.077

2.50

0.065

2.64

0.162

0.609

 16:4n-3

1.27a

0.034

1.16ab

0.038

1.08b

0.035

0.890c

0.042

< 0.001

 18:0

13.8a

0.138

13.1b

0.204

13.5ab

0.213

12.9b

0.228

0.004

 18:1n-9

7.84b

0.073

8.50a

0.058

8.00ab

0.257

8.04ab

0.281

< 0.001

 18:1n-7

2.24a

0.067

2.29a

0.051

2.21a

0.048

1.92b

0.047

< 0.001

 18:2n-6

13.2a

0.130

11.6b

0.195

11.1b

0.172

11.2b

0.424

< 0.001

 19:0

0.090a

0.009

0.070b

0.002

0.080a

0.002

0.080a

0.005

< 0.001

 18:3n-3

0.140a

0.019

0.090b

0.004

0.060c

0.005

0.070bc

0.011

< 0.001

 20:0

0.110ab

0.006

0.090b

0.006

0.100ab

0.005

0.130a

0.013

0.047

 20:1n-9

0.080b

0.005

0.400a

0.043

0.070b

0.009

0.090b

0.012

< 0.001

 20:1n-7

0.077

0.006

0.094

0.007

0.086

0.009

0.085

0.004

0.339

 20:2n-6

0.370a

0.023

0.200b

0.024

0.170b

0.009

0.190b

0.016

< 0.001

 20:4n-6

20.5a

0.617

14.6c

0.570

17.7b

0.172

17.9b

0.725

< 0.001

 20:4n-3

0.410ab

0.386

0.080b

0.012

0.060b

0.002

0.490a

0.110

< 0.001

 20:5n-3

0.260c

0.026

3.08a

0.114

2.33b

0.054

0.470c

0.254

< 0.001

 22:0

0.290b

0.026

0.270b

0.032

0.280b

0.009

0.390a

0.354

0.002

 22:4n-6

1.51a

0.118

0.250d

0.023

0.550b

0.021

0.390c

0.281

< 0.001

 22:5n-6

0.340b

0.021

0.100d

0.007

0.140c

0.008

1.75a

1.50

< 0.001

 22:5n-3

1.94bc

0.426

2.55b

0.177

3.50a

0.094

0.950c

0.654

< 0.001

 24:0

0.890

0.089

0.827

0.077

0.849

0.038

0.932

0.625

0.747

 22:6n-3

1.22c

0.097

4.24b

0.353

0.680d

0.061

5.78a

0.484

< 0.001

 24:1n-9

0.452

0.046

0.570

0.070

0.400

0.032

ND

0.106

 Others

1.69b

0.029

2.37a

0.080

2.47a

0.026

1.76b

0.057

< 0.001

Partial sums and ratios

 Total SFA

43.0

1.16

44.2

1.03

45.5

0.646

44.3

0.896

0.221

 Total MUFA

11.4b

0.119

12.8a

0.148

11.8ab

0.396

10.9b

0.332

< 0.001

 Total PUFA

43.9a

1.14

40.7ab

1.11

40.2b

0.389

43.1a

1.00

0.008

 Total n-3

7.68c

0.701

13.6a

0.691

10.2b

0.155

11.3a

0.556

< 0.001

 Total n-6

35.9a

0.659

26.8d

0.457

29.7c

0.166

31.4b

0.576

< 0.001

n-3/n-6

0.214c

0.018

0.509a

0.018

0.344b

0.004

0.359b

0.015

< 0.001

n = 8 per group. ND, not detected. Total SFA = 14:0 + 15:0 + 16:0anteiso + 16:0 + 17:0isobr + 17:0 + 18:0 + 19:0 + 20:0 + 22:0 + 24:0; Total MUFA = 16:1n-9 + 16:1n-7 + 17:1 + 18:1n-9 + 18:1n-7 + 20:1n-9 + 20:1n-7 + 24:1n-9; Total PUFA = 16:3n-4 + 16:3n-3 + 16:4n-3 + 18:2n-6 + 18:3n-3 + 20:2n-6 + 20:4n-6 + 20:4n-3 + 20:5n-3 + 22:4n-6 + 22:5n-6 + 22:5n-3 + 22:6n-3; Total n-3 = 16:3n-3 + 16:4n-3 + 18:3n-3 + 20:4n-3 + 20:5n-3 + 22:5n-3 + 22:6n-3; Total n-6 = 18:2n-6 + 20:2n-6 + 20:4n-6 + 22:4n-6 + 22:5n-6. a,b,c Means in the same row with different superscripts are statistically different (PDIFF adjust Tukey, P < 0.05)

Fatty acid composition and major phospholipid classes in brain

FA composition in brain is presented in Table 6. Whereas the liver displayed the highest number of variations depending on diet, the brain tissue was less responsive. SFA, MUFA, PUFA and n-3 PUFA were unchanged across dietary treatments (P > 0.05). n-6 PUFA was higher in Milk Fat in comparison to Fish Oil (P = 0.018), but identical to Nanno and Schyzo, most at the expenses of LA (P = 0.011) and 22:4n-6 (P = 0.031). The n-3/n-6 ratio reached the highest value in Fish Oil fed rats relative to Milk Fat and Nanno (P = 0.000). As expected, EPA was not detected in Milk Fat and it was best incorporated in Fish Oil fed rats (P = 0.000). DHA did not vary across diets (P > 0.05).
Table 6

Total FAME (mg/g), fatty acid composition (% total fatty acids) and major phospholipid classes in brain

 

Milk Fat

Fish Oil

Nanno

Schyzo

Significance

Mean

SE

Mean

SE

Mean

SE

Mean

SE

 

Total FAME

153

8.04

175

12.1

169

8.08

157

5.01

0.354

Fatty acids

 14:0

0.172

0.010

0.156

0.021

0.147

0.016

0.144

0.013

0.365

 16:0anteiso

2.23

0.101

2.14

0.089

2.36

0.180

2.13

0.863

0.641

 16:0

18.9

0.819

18.6

1.42

18.9

1.26

17.6

0.011

0.692

 16:1n-9

0.112

0.006

0.120

0.008

0.114

0.007

0.093

0.021

0.293

 16:1n-7

0.380

0.019

0.444

0.039

0.407

0.025

0.379

0.021

0.406

 16:3n-4

0.239

0.024

0.284

0.025

0.217

0.028

0.246

0.033

0.348

 16:3n-3

3.90

0.055

4.10

0.086

4.36

0.259

4.03

0.057

0.095

 16:4n-3

1.45

0.119

1.40

0.066

1.44

0.057

1.42

0.086

0.963

 18:0

18.9

0.382

19.6

0.181

19.9

0.332

19.2

0.283

0.174

 18:1n-9

15.8

0.427

16.6

0.277

15.9

0.246

16.1

0.483

0.238

 18:1n-7

3.03

0.095

2.93

0.041

3.01

0.031

2.88

0.085

0.239

 18:2n-6

1.04a

0.064

0.920ab

0.038

0.810b

0.028

0.830ab

0.082

0.011

 19:0

0.047

0.005

0.051

0.002

0.052

0.004

0.055

0.002

0.420

 18:4n-3

0.051

0.004

0.045

0.008

0.059

0.006

0.052

0.002

0.569

 20:0

0.459

0.069

0.437

0.036

0.443

0.035

0.442

0.038

0.994

 20:1n-9

1.44

0.286

1.33

0.144

1.36

0.103

1.44

0.172

0.962

 20:1n-7

0.449

0.077

0.398

0.037

0.413

0.030

0.430

0.044

0.915

 20:2n-6

0.151

0.019

0.110

0.008

0.120

0.007

0.097

0.008

0.050

 20:4n-6

10.1

0.284

9.28

0.209

9.60

0.476

9.59

0.181

0.202

 20:5n-3

ND

0.070a

0.006

0.040b

0.004

0.020c

0.003

0.000

 22:0

0.478

0.074

0.407

0.049

0.429

0.055

0.456

0.051

0.844

 22:1n-11

0.221

0.045

0.176

0.024

0.197

0.019

0.199

0.031

0.810

 22:1n-9

0.101

0.004

0.113

0.011

0.115

0.015

0.123

0.025

0.552

 23:0

0.241

0.013

0.235

0.023

0.279

0.035

0.247

0.018

0.736

 22:4n-6

3.21a

0.144

2.52b

0.185

2.98ab

0.183

2.73ab

0.163

0.031

 22:5n-6

0.804

0.099

0.532

0.187

0.719

0.312

0.940

0.061

0.192

 22:5n-3

0.280ab

0.064

0.340a

0.019

0.410a

0.036

0.160b

0.008

0.000

 24:0

1.11

0.141

0.893

0.115

0.991

0.163

0.999

0.099

0.705

 22:6n-3

11.4

0.601

13.0

0.707

10.9

0.857

13.1

0.724

0.084

 24:1n-9

1.43

0.252

1.14

0.162

1.27

0.211

1.25

0.167

0.800

 Others

1.88a

0.119

1.58b

0.084

2.13a

0.158

2.66a

0.166

0.000

Partial sums and ratios

 Total SFA

42.6

0.891

42.6

1.40

43.5

1.40

41.2

1.01

0.634

 Total MUFA

23.0

1.07

23.2

0.545

22.8

0.311

22.9

0.814

0.886

 Total PUFA

32.5

0.871

32.6

1.09

31.6

1.34

33.2

1.03

0.787

 Total n-3

17.0

0.536

19.0

0.835

17.2

0.816

18.8

0.697

0.084

 Total n-6

14.5a

0.436

12.8b

0.339

13.5ab

0.570

13.3ab

0.332

0.018

n-3/n-6

1.18c

0.035

1.48a

0.048

1.27bc

0.036

1.42ab

0.025

0.000

Major phospholipid classes

 NPL

31.1b

0.934

34.0ab

1.37

36.0a

0.861

33.6ab

2.73

0.023

 PE

33.4

0.732

33.4

0.956

31.9

0.621

34.3

1.55

0.288

 PS

21.9

1.21

20.5

2.03

20.5

0.658

18.3

1.89

0.468

 PC

13.6a

0.141

12.1ab

0.706

11.6b

0.523

13.9ab

0.776

0.016

n = 8 per group. ND, not detected. NPL, non-polar lipids; PE, phosphatidylethanolamine; PS, phosphatidylserine; PC, phosphatidylcholine. Total SFA = 14:0 + 16:0anteiso + 16:0 + 18:0 + 19:0 + 20:0 + 22:0 + 23:0 + 24:0; Total MUFA = 16:1n-9 + 16:1n-7 + 18:1n-9 + 18:1n-7 + 20:1n-9 + 20:1n-7 + 22:1n-11 + 22:1n-9 + 24:1n-9; Total PUFA = 16:3n-4 + 16:3n-3 + 16:4n-3 + 18:2n-6 + 18:4n-3 + 20:2n-6 + 20:4n-6 + 20:5n-3 + 22:4n-6 + 22:5n-6 + 22:5n-3 + 22:6n-3; Total n-3 = 16:3n-3 + 16:4n-3 + 18:4n-3 + 20:5n-3 + 22:5n-3 + 22:6n-3; Total n-6 = 18:2n-6 + 20:2n-6 + 20:4n-6 + 22:4n-6 + 22:5n-6. a,b,c Means in the same row with different superscripts are statistically different (PDIFF adjust Tukey, P < 0.05)

The major phospholipids classes in brain are also shown in Table 6. In comparison to Milk Fat, Nanno fed rats had increased non-polar lipids (NPL) but decreased phosphatidylcholine (PC) (P < 0.05). No additional changes were found for phosphatidylethanolamine (PE) and phosphatidylserine (PS) fractions across dietary groups (P > 0.05).

Behaviour, serotonin and catecholamines

The FST outcomes are presented in Table 7 along with serotonin and catecholamines levels in plasma. Rats fed Nanno and Schyzo diets spent more time floating than rats fed Fish Oil (P < 0.05). In turn, Nanno had more time immobile than Schyzo (P < 0.05). Climbing and swimming were unchanged (P < 0.05) by diet. Adrenalin was increased in Schyzo relative to Milk Fat (P < 0.05). Fish Oil fed rats had higher dopamine levels than Nanno (P < 0.05). Serotonin and noradrenalin presented similar values across dietary treatments (P < 0.05).
Table 7

FST outcomes, serotonin and catecholamines in plasma

 

Milk Fat

Fish Oil

Nanno

Schyzo

Significance

Mean

SE

Mean

SE

Mean

SE

Mean

SE

 

Climbing (s)

59.5

9.75

75.5

10.1

57.0

14.0

68.3

14.2

0.628

Swimming (s)

119

20.1

125

24.3

82.1

13.3

135

18.7

0.110

Floating (s)

58.4ab

8.37

37.7b

5.82

78.9a

14.2

67.8a

6.41

0.006

Immobile (s)

67.7ab

19.1

58.8ab

21.3

76.0a

13.5

24.8b

6.36

0.006

Total Movement (s)

179

21.7

200

26.1

150

22.7

208

10.3

0.137

Total Immobile (s)

126

21.4

104

25.8

155

22.6

96.7

9.96

0.125

Serotonin (μg/l)

76.3

32.8

21.4

9.73

49.9

13.9

114

41.1

0.061

Noradrenalin (ng/l)

1257

89.1

1377

128

1442

152

1806

184

0.082

Adrenalin (ng/l)

1826b

402

3098ab

561

4117ab

1296

4889a

904

0.016

Dopamine (ng/l)

78.9ab

18.4

115a

23.5

43.1b

10.5

58.9ab

14.4

0.047

n = 8 per group. a,b,c Means in the same row with different superscripts are statistically different (PDIFF adjust Tukey, P < 0.05)

Neuromodulation transcriptional profile

The transcriptional profile of HT1A, HT2A, BDNF, CREB, TNF-α and IL-6 in the hippocampus of rats fed Milk Fat, Fish Oil, Nanno and Schyzo diets are shown in Fig. 1. A similar pattern of variations was found for HT1A, HT2A and CREB being these genes consistently downregulated in Milk Fat in comparison to n-3 LCPUFA diets (P < 0.05). BDNF gene was upregulated by Schyzo diet (P < 0.05). The gene expression levels of IL-6 were equally higher in Fish Oil and Nanno fed rats, and lower in Schyzo (P < 0.05). mRNA levels of TNF-α were similar across dietary groups (P > 0.05). Moreover, mRNA expression levels of HT1A, HT2A and CREB were moderately (0.7 ≥ r ≥ 0.3) positively correlated with n-3/n-6 PUFA ratio in erythrocytes (r = 0.532, P = 0.002; r = 0.673, P < 0.001; r = 0.539, P = 0.001, respectively).
Fig. 1

Effect of dietary treatments on the relative expression levels of serotonin 5-HT1A receptor (HT1A), serotonin 5-HT2A receptor (HT2A), brain-derived neurotrophic factor (BDNF), cAMP responsive element binding protein (CREB), tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) in the hippocampus. Means ± standard error (SE). Means with different letters are significantly different (PDIFF adjust Tukey, P < 0.05)

Discussion

Facing the premise that EPA and DHA are a safe and inexpensive link to a healthier long life devoid of neurological disturbances, this investigation is of utmost importance to promote sustainability of marine lipid resources and to reduce the environmental impact of fishery without compromising human health needs.

The potential of EPA and DHA to reduce cholesterol levels using experimental animal models has been widely reported [32, 33]. Recently, Ramsden et al. [34] demonstrated that reducing serum cholesterol does not translate into a lower risk from coronary heart disease and improved human survival, increasing the debate on this topic. Notwithstanding, the biggest reduction on LDL-cholesterol was observed in Fish Oil, rather than in Nanno or Schyzo comparative to Milk Fat fed rats. This might be related to the fact that those microalgae enriched diets contained only EPA or DHA, instead of the combined form. Moreover, EPA and DHA combined as well as single EPA reduced total lipids in plasma, in opposition to single DHA; hence, the positive effects found might be due to EPA action. TAG values were higher in Milk Fat fed rats in comparison to the others. Once again, this effect derives from the fact that milk fat did not contain EPA or DHA. Glucose was higher in Milk Fat and lower in n-3 LCPUFA enriched diets. Although controversial, several studies point to a diabetogenic effect of SFA with respect to PUFA [35, 36]. This seems to be the case here, given the fact that glucose was higher in rats fed only with Milk Fat. Hepatic markers were measured to determine if microalgae (Nannochloropsis and Schizochytrium) could be toxic. This is a crucial fact because DHA increases the activity of detoxification enzymes in the liver [37], as verified in Fish Oil and Schyzo fed rats for AST and ALT. Even if AST was deviated from the reference values (42.9 ± 10.1 U/l) [38], n-3 LCPUFA enriched diets did not affect liver and renal function, as indicated by the normal values of urea and creatinine. The small variations observed among dietary groups are believed to have no pathophysiological impact.

Regarding cytokines, the non-variation of systemic TNF-α and gene expression levels in the hippocampus is somewhat surprising as high levels of this pro-inflammatory marker were expected in Milk Fat fed rats. Moreover, anti-inflammatory effects have been assigned to dietary EPA and DHA [39, 40]. As far as IL-6 concerns, contradictory findings were observed for this pleiotropic circulating cytokine secreted by many cell types [41]: on the one hand, Schyzo diet increased IL-6 concentration in plasma; on the other hand, IL-6 was down-regulated in the hippocampus of the same dietary group, making it very hard to draw definite conclusions, even if these determinations were performed in different tissues. IL-6 has been reported to increase hepatic synthesis of cholesterol [41] which possibly explains the high levels of cholesterol found in Schyzo fed rats relative to the other n-3 LCPUFA diets.

The FA profile in faeces was assessed to determine FA loss, compared to the amount provided by diet. The fatty acid content was higher in Fish Oil and lower in Nanno which means that Nanno fed rats had a higher absorption of FA in the organism. Nannochloropsis is indeed efficiently incorporated into the blood, liver and brain lipids of rats [32]. EPA was found higher in Nanno and residual in Fish Oil, which concurs with diet composition. The same explanation applies to Milk Fat or Schyzo with no traces of EPA in faeces. As expected, DHA was not detected in faeces of any dietary group because DHA is highly retained by the body [42, 43].

Liver is the key organ in lipid and lipoprotein metabolism [44]. It is very sensitive to dietary FA variations [44], as observed here. Indeed, n-6 PUFA content declined while n-3 PUFA generally increased with substitution of fat richer in n-3 LCPUFA, thus leading to a marked improvement in n-3/n-6 ratio. These changes may be mainly attributed to LA reduction and to EPA and DHA overall increase and corroborate previous studies in which liver FA profile displayed approximately 2-fold increase of DHA% after dietary supplementation with DHA and other n-3 LCPUFA [44, 45]. Moreover, liver is considered to be the major site for the conversion of ALA into DHA [46]. Our results seem to contradict Barceló-Coblijn and Murphy [47], who reported that dietary ALA is a crucial source of n-3 LCPUFA for maintaining these FA tissue contents. In this particular case, it can be argued that ALA content was still insufficient for offsetting the effects of the large amount of milk fat.

The FA profile of erythrocytes, representative of systemic FA bioavailability, showed similar alterations to the liver, although in a lower magnitude. PUFA levels were higher than MUFA, which was expected since PUFA was lower in faeces, indicating a better absorption of these FA by the organism. Within PUFA, n-6 was found higher over n-3, which is also logical because all diets had higher n-6 relative to n-3. ARA concentrations were elevated in rats fed high levels of LA, likely as a result of higher ARA synthesis rates [48]. EPA, although found in residual levels (less than 1%), was higher in Fish Oil than in Nanno fed rats and this result contradicts diet composition. The reason for this finding is that EPA was more converted to 22:5n-3, a downstream product of EPA in Nanno fed rats. DHA was found higher in Schyzo and lower in Nanno which was expected because Nanno diet had no DHA. The residual levels found might be due to the biosynthesis of DHA from the n-3 precursor (ALA) [49] or by EPA in the Nanno group [50]. The same conversion might also have happened in Milk Fat group. Taking into account the highest percentage of n-3 PUFA and EPA, and also a high percentage of DHA in erythrocytes, Fish Oil is proven the best dietary source for systemic incorporation of these FA in the organism.

On a per-weight basis, brain is the tissue richest in lipids [51]. It is the most conservative organ in terms of DHA uptake [43, 44] where it composes ~10% of total FA [52]. DHA is essential for maintaining normal brain structure, function and metabolism and its concentration depends on dietary DHA content as well as liver synthesis from its shorter chain nutritionally essential PUFA precursor ALA [49]. In fact, DHA synthesis directly in brain tissues is very low [53]. Herein, the non-variation of DHA reinforces the notion that DHA is rapidly absorbed and retained in brain cell membranes [42]. We speculate that the levels found might have been incorporated prior to the administration of DHA, through diet [54]. Any ability to detect changes in EPA in the brain is unexpected. EPA is rapidly and extensively β-oxidised upon entry into the brain [55]. Anyway, we found that rats fed Fish Oil had the highest % of EPA, followed by Nanno and Schyzo groups. These data are in accordance with EPA levels found in erythrocytes and faeces, in which Fish Oil group presented the highest and lowest % of EPA, respectively. The undetected EPA in Milk Fat fed rats correlates well with diet composition.

FA composition of the two major phospholipids classes, PE and PC, was found to be specific: PC contains mostly SFA and 18:1 fatty acids, while PE is rich in PUFA [56]. Changes in SFA/PUFA ratio are likely to influence cellular function, which could impair neurophysiological performances [57, 58]. Even if we failed to characterise the FA composition in brain phospholipid classes, our data suggest a compensatory mechanism of reduced PC fraction while increasing NPL (the majority of which is composed of cholesterol) between Nanno and Milk Fat dietary groups. The lipid class-dependent nature of these variations reflects generally differences in intake and metabolism [59]. Lamaziere et al. [51] reported that the provision of fish oil to rats did not modify PS, in accordance to our data, but increased the proportion of DHA-containing PC. The PE fraction, in which DHA accounts for around 25% (wt%) of total FA [60] was similarly altered by n-3 PUFA administration [51], in contrast to our findings.

With respect to FST parameters, it would be expected higher immobile and floating times in Milk Fat (without n-3 LCPUFA supplementation) fed rats because these behaviours are recognised as passive and non-active indicators, respectively [26]. Regarding immobility, Nanno fed rats spent more time immobile than Schyzo. DHA has been referred as a possible nutrient for retarding depression and anxiety, supporting the lower immobility time found in Schyzo. Notwithstanding, the immobility time found in Milk Fat was lower than expected and not consistent with the hypothesis initially proposed or with other studies [5, 61]. The lack of positive behaviour in Nanno fed rats can be explained by the high levels of EPA found in faeces. Regarding floating time, Nanno and Schyzo were similar to each other, but higher than Fish Oil. Once more, this possibly indicates that single EPA or DHA are not as beneficial as EPA + DHA, in agreement with observations by Mozaffarian and Wu [62] on cardiovascular health. The only setback is that floating time was also identical between Milk Fat and Fish Oil. In fact, Milk Fat behavioural outcomes were similar to other dietary groups. The presence of DHA in brain of rats fed Milk Fat, in identical amounts to those of n-3 LCPUFA enriched diets, can help to explain this similarity.

Adrenalin is a stress hormone [63] whose levels seem to decrease with fish oil administration [64, 65]. A tendency for reduced adrenalin was observed in Fish Oil fed rats relative to Nanno and Schyzo, in accordance with literature [64, 65]. However, Milk Fat group had the lowest adrenalin levels but this diet did not contain EPA or DHA. Moreover, its levels are similar to those found in both Fish Oil and Nanno, but different from Schyzo, leading us to the assumption that neither EPA nor DHA affect adrenalin system, with EPA having a less predominant role, contradicting other reports. On the topics of catecholamines regulation, low levels of dopamine have been associated with PUFA deficiency [6567]. Higher levels of dopamine were found in Fish Oil group whereas lower were found in Nanno. Therefore, it can be assumed that EPA alone has a smaller impact on regulating dopaminergic system, than combined with DHA.

HT1A and HT2A are related to neural function. Levant et al. [68] have shown that rats with low levels of DHA in brain have less serotonin (5-HT) and higher hippocampal density of 5-HT1A. Serotonin in plasma was found similar across dietary groups although a tendency for high levels were found in Schyzo fed rats, which concurs with diet composition. The transcriptional profile of HT1A and HT2A was consistently upregulated by EPA, DHA or both FA, rather than only by DHA. Accordingly, more research on this subject is required. The variation of CREB expression is positive, given its role in learning and memory, brain traumas recovery and stress [69]. Although not consensual [68], it corroborates the literature pointing towards the normalization of CREB by n-3 LCPUFA enriched diets. Also, HT1A, HT2A and CREB mRNA levels in hippocampus were found positively correlated with n-3/n-6 PUFA in erythrocytes. This ratio is considered a biomarker of systemic inflammation [70, 71] consolidating, once again, the neuroprotective effects of EPA and DHA. CREB is also a transcription factor contributing for BDNF regulation [72, 73]. This later gene was found powerfully expressed by individual DHA.

Conclusions

The underlying hypothesis of this study was that EPA and DHA would have distinct neurobiological effects, if ingested singly or combined, using alternative marine lipid sources as n-3 LCPUFA rich microalgae in Wistar rats. FST revealed the potential benefit of fish oil (EPA + DHA) compared to microalgae oils (EPA or DHA singly). These results could be ascribed to high concentrations of systemic dopamine and n-3 LCPUFA incorporation in liver and erythrocytes, suggesting that fish oil is a better dietary source for FA deposition in the organism. Moreover, each tissue, liver, erythrocytes and brain, showed a particular FA profile with specific traits. Another positive impact of a diet rich in both EPA and DHA was the mitigation of plasma metabolites unbalance, in particular through reduction of total lipids and LDL-C/HDL-C ratio. In turn, EPA provided by Nannochloropsis microalga had similar results, although with a lower magnitude as EPA and DHA combined, in opposition to DHA provided by Schizochytrium microalga, allowing us to conclude that the protective effects on plasma lipid profile might be due, to a large extent, to EPA action. Apart from the positive variation of BDNF mRNA levels by DHA alone, the combination of EPA and DHA can provide protection against reduced plasticity and impaired learning ability by upregulating HT1A, HT2A and CREB genes in the hippocampus. Taken together, a diet enriched in EPA + DHA form seems more adequate for health promotion, in various critical domains of neurophysiology and lipid metabolism, which can benefit, in the long run, neuronal structure and function.

Abbreviations

γ-GT: 

gamma glutamyl transferase

AA: 

arachidonic acid

ALA: 

α-linolenic acid

ALP: 

alkaline phosphatase

ALT: 

alanine aminotransferase

AST: 

aspartate aminotransferase

BDNF: 

brain-derived neurotrophic factor

CREB: 

cAMP responsive element binding protein

DHA: 

docosahexaenoic acid

EPA: 

eicosapentaenoic acid

FA: 

fatty acid

FAME: 

fatty acid methyl esters

FST: 

forced swimming test

HT1A: 

serotonin 5-HT1A receptor

HT2A: 

serotonin 5-HT2A receptor

IL-6: 

interleukin-6

LA: 

linoleic acid

n-3 LCPUFA: 

n-3 long chain polyunsaturated fatty acids

NPL: 

non-polar lipids

PC: 

phosphatidylcholine

PE: 

phosphatidylethanolamine

PS: 

phosphatidylserine

TAG: 

triacylglycerols

TNF-α: 

tumour necrosis factor alpha

Declarations

Acknowledgments

The authors acknowledge Júlia Ferreira from IPMA regarding lipid analyses.

Funding

This study was supported by the Spanish Ministry of Science and Innovation through “Structured lipids: novel dietary strategies for improving human health” grant (AGL/25807/2011) and by Fundação para a Ciência e a Tecnologia (FCT, Lisbon, Portugal) through CIISA project (UID/CVT/00276/2013). PAL is a researcher from Incentivo 2014 project (AGR/UI0276/2014). SVM, CC and CA are recipients of individual fellowships from FCT (SFRH/BPD/63019/2009, SFRH/BPD/102689/2014 and SFRH/BPD/64951/2009, respectively).

Availability of data and materials

The datasets analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

PAL, SVM and MSM performed the animal experiment. JLGG and JM performed the behaviour test. PAL, SVM, CMA, MCP and RMAP conducted the laboratory work. PAL, CC and CA prepared the manuscript. NMB, JLGG and JAMP were responsible for the experimental design, interpretation of results and final version of the manuscript. All authors read and approved the final manuscript.

Ethics approval

The experimental procedures were reviewed by the Ethics Commission of CIISA/FMV and approved by the Animal Care Committee of the National Veterinary Authority (Direcção-Geral de Alimentação e Veterinária, Portugal), following the appropriate European Union guidelines (2010/63/EU Directive) to minimise animal suffering.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
CIISA, Faculdade de Medicina Veterinária, Universidade de Lisboa
(2)
DIVAV, Instituto Português do Mar e da Atmosfera (IPMA)
(3)
CIIMAR, Universidade do Porto
(4)
Depsiextracta - Tecnologias Biológicas, Lda., Quinta do Monte Novo-Taipadas
(5)
iMed.UL, Faculdade de Farmácia, Universidade de Lisboa
(6)
Joaquim Chaves Saúde. Dr. Joaquim Chaves, Laboratório de Análises Clínicas
(7)
Departamento de Tecnología de Alimentos, Universidad de Almería

References

  1. Harman D. The aging process (free radicals/evolution/antioxidants/degenerative diseases/longevity). PNAS. 1981;78:7124–8.View ArticlePubMedPubMed CentralGoogle Scholar
  2. WHO, World Health Organization. Ageing and life course: interesting facts about ageing. 2012 (available online at http://www.who.int/ageing/about/facts/en/).
  3. Klenk J, Keil U, Jaensch A, Christiansen MC, Nagel G. Changes in life expectancy 1950–2010: contributions from age- and disease- specific mortality in selected countries. Popul Health Metrics. 2016;14:20.View ArticleGoogle Scholar
  4. Dyall SC, Michael-Titus AT. Neurological benefits of omega-3 fatty acids. NeuroMolecular Med. 2008;10:219–35.View ArticlePubMedGoogle Scholar
  5. Ferraz AC, Delattre AM, Almendra RG, Sonagli M, Borges C, Araujo P, Andersen ML, Tufik S, Lima MM. Chronic ω-3 fatty acids supplementation promotes beneficial effects on anxiety, cognitive and depressive-like behaviors in rats subjected to a restraint stress protocol. Behav Brain Res. 2011;219:116–22.View ArticlePubMedGoogle Scholar
  6. Cutuli D, De Bartolo P, Caporali P, Laricchiuta D, Foti F, Ronci M, Rossi C, Neri C, Spalletta G, Caltagirone C, Farioli-Vecchioli S, Petrosini L. n-3 polyunsaturated fatty acids supplementation enhances hippocampal functionality in aged mice. Front Aging Neurosci. 2014;6:220. https://doi.org/10.3389/ fnagi.2014.00220.Google Scholar
  7. Molfino A, Gioia G, Rossi Fanelli F, Muscaritoli M. The role for dietary omega-3 fatty acids supplementation in older adults. Nutrients. 2014;6:4058–72.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Logan AC. Neurobehavioral aspects of omega-3 fatty acids: possible mechanisms and therapeutic value in major depression. Altern Med Ver. 2003;8:410–25.Google Scholar
  9. Chalon S, Delion-Vancassel S, Belzung C, Guilloteau D, Leguisquet AM, Besnard JC, Durand G. Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J Nutr. 1998;128:2512–9.PubMedGoogle Scholar
  10. Burdge GC, Finnegan YE, Minihane AM, Williams CM, Wootton CA. Effect of altered dietary n-3 fatty acid intake upon plasma lipid fatty acid composition, conversion of [13C]alpha-linolenic acid to longer-chain fatty acids and partitioning towards beta-oxidation in older men. Brit J Nutr. 2003;90:311–21.View ArticlePubMedGoogle Scholar
  11. Calder PC. Mechanisms of action of (n-3) fatty acids. J Nutr. 2012;142:592S–9.View ArticlePubMedGoogle Scholar
  12. Adarme-Vega TC, Thomas-Hall SR, Schenk PM. Towards sustainable sources for omega-3 fatty acids production. Curr Opin Biotechnol. 2014;26:14–8.View ArticlePubMedGoogle Scholar
  13. Winwood RJ. Recent developments in the commercial production of DHA and EPA rich oils from micro-algae. OCL. 2013;20:D604.View ArticleGoogle Scholar
  14. Marangoni F, Poli A. n-3 fatty acids: functional differences between food intake, oral supplementation and drug treatments. Int J Cardiol. 2013;170:S12–5.View ArticlePubMedGoogle Scholar
  15. Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci. 2015;7:52.Google Scholar
  16. Bozzatello P, Brignolo E, De Grandi E, Bellino S. Supplementation with omega-3 fatty acids in psychiatric disorders: a review of literature data. J Clin Med. 2016;5:67. https://doi.org/10.3390/jcm5080067.View ArticlePubMed CentralGoogle Scholar
  17. Russell FD, Bürgin-Maunder CS. Distinguishing health benefits of eicosapentaenoic and docosahexaenoic acids. Mar Drugs. 2012;10:2535–59.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Song C, Shieh CH, Wu YS, Kalueff A, Gaikwad S, Su KP. The role of omega-3 polyunsaturated fatty acids eicosapentaenoic and docosahexaenoic acids in the treatment of major depression and Alzheimer’s disease: acting separately or synergistically? Prog Lipid Res. 2016;62:41–54.View ArticlePubMedGoogle Scholar
  19. AOAC. Official Methods of Analysis, 17th ed. Association of Official Analytical Chemists: Gaithersburg, MA, USA; 2000.Google Scholar
  20. Bandarra NM, Batista I, Nunes ML, Empis JM. Seasonal variation in the chemical composition of horse-mackerel (Trachurus trachurus). Eur Food Res Technol. 2001;212:535–9.View ArticleGoogle Scholar
  21. Ratledge C. Fatty acid biosynthesis in microorganisms being used for single cell oil production. Biochimie. 2004;86:807–15.View ArticlePubMedGoogle Scholar
  22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.PubMedGoogle Scholar
  23. Covaci A, Voorspoels S, Thomsen C, van Bavel B, Neels H. Evaluation of total lipids using enzymatic methods for the normalization of persistent organic pollutant levels in serum. Sci Total Environ. 2006:361–6.Google Scholar
  24. Bligh E, Dyer W. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911–7.View ArticlePubMedGoogle Scholar
  25. Bandarra NM, Batista I, Nunes ML, Empis JM, Christie WW. Seasonal changes in lipid composition of sardine Sardina pilchardus. J Food Sci. 1997;62:40–3.View ArticleGoogle Scholar
  26. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature. 1977;266:730–2.View ArticlePubMedGoogle Scholar
  27. Crispim Junior CF, Pederiva CN, Bose RC, Garcia VA, Lino-de-Oliveira C, Marino-Neto J. ETHOWATCHER: validation of a tool for behavioral and video-tracking analysis in laboratory animals. Comp Biol Med. 2012;42:257–64.View ArticleGoogle Scholar
  28. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:RESEARCH0034.Google Scholar
  29. Andersen CL, Jensen JL, Orntoft T. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004;64:5245–50.View ArticlePubMedGoogle Scholar
  30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8.View ArticlePubMedGoogle Scholar
  31. Fleige S, Pfaffl MW. RNA integrity and the effect on the real-time qRT-PCR performance. Mol Asp Med. 2006;27:126–39.View ArticleGoogle Scholar
  32. Werman MJ, Sukenik A, Mokady S. Effects of the marine unicellular alga Nannochloropsis sp. to reduce the plasma and liver cholesterol levels in male rats fed on diets with cholesterol. Biosci Biotechnol Biochem. 2003;67:2266–8.View ArticlePubMedGoogle Scholar
  33. Boudrault C, Bazinet RP, Ma DWL. Experimental models and mechanisms underlying the protective effects of n-3 polyunsaturated fatty acids in Alzheimer's disease. J Nutr Biochem. 2009;20:1–10.View ArticlePubMedGoogle Scholar
  34. Ramsden CE, Zamora D, Majchrzak-Hong S, Faurot KR, Broste SK, Frantz RP, Davis JM, Ringel A, Suchindran CM, Hibbeln JR. Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronoary Experiment (1968-73). BMJ. 2016;353:i1246.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Geng T, Hu W, Broadwater MH, Snider JM, Bielawski J, Russo SB, Schwacke JH, Ross J, Cowart LA. Fatty acids differentially regulate insulin resistance through endoplasm reticulum stress-mediated induction of tribbles homologue 3: a potential link between dietary fat composition and the pathophysiological outcomes of obesity. Diabetologia. 2013;56:2078–87.View ArticlePubMedGoogle Scholar
  36. Pereira S, Breen DM, Naassan AE, Wang PY, Uchino H, Fantus IG, Carpentier AC, Gutierrez-Juarez R, Brindley DN, Lam TK, Giacca A. In vivo effects of polyunsaturated, monounsaturated, and saturated fatty acids on hepatic and peripheral insulin sensitivity. Metabolism. 2015;64:315–22.View ArticlePubMedGoogle Scholar
  37. Demoz A, Asiedu DK, Lie O, Berge RK. Modulation of plasma and hepatic oxidative status and changes in plasma lipid profile by n-3 (EPA and DHA), n-6 (corn oil) and a 3-thia fatty acids in rats. Biochim Biophys Acta. 1994;1199:238–44.View ArticlePubMedGoogle Scholar
  38. Kaneko JJ, Harvey JW, Bruss ML. Clinical Biochemistry of Domestic Animals. 6th ed. Burlington, MA, USA: Academic Press; 2008.Google Scholar
  39. Calder PC. Fatty acids and inflammation: the cutting edge between food and pharma. Eur J Pharmacol. 2011;668:S50–8.View ArticlePubMedGoogle Scholar
  40. Serhan CN, Petasis NA. Resolvins and protectins in inflammation-resolution. Chem Rev. 2011;111:5922–43.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol. 2006;64:335–65.Google Scholar
  42. Wurtman RJ. A nutrient combination that can affect synapse formation. Nutrients. 2014;6:1701–10.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Bradbury J. Docosahexaenoic acid (DHA): an ancient nutrient for the modern human brain. Nutrients. 2011;3:529–54.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Bandarra NM, Lopes PA, Martins SV, Ferreira J, Alfaia CM, Rolo EA, Correia JJ, Pinto RM, Ramos-Bueno RP, Batista I, Prates JA, Guil-Guerrero JL. Docosahexaenoic acid at the sn-2 position of structured triacylglycerols improved n-3 polyunsaturated fatty acid assimilation in tissues of hamsters. Nutr Res. 2016;36:452–63.View ArticlePubMedGoogle Scholar
  45. Lee KT, Akoh CC, Dawe DL. Effects of structured lipid containing omega 3 and medium chain fatty acids on serum lipids and immunological variables in mice. J Food Biochem. 1999;23:197–208.View ArticleGoogle Scholar
  46. Rapoport SI, Rao JS, Igarashi M. Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver. Prostaglandins Leukot Essent Fatty Acids. 2007;77:251–61.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Barceló-Coblijn G, Murphy EJ. Alpha-linolenic acid and its conversion to longer chain n-3 fatty acids: benefits for human health and a role in maintaining tissue n-3 fatty acid levels. Prog Lipid Res. 2009;48:355–74.View ArticlePubMedGoogle Scholar
  48. Domenichiello AF, Kitson AP, Chen CT, Trépanier MO, Stavro PM, Bazinet RP. The effect of linoleic acid on the whole body synthesis rates of polyunsaturated fatty acids from α-linolenic acid and linoleic acid in free-living rats. J Nutr Biochem. 2016;30:167–76.View ArticlePubMedGoogle Scholar
  49. Rapoport SI, Ramadan E, Basselin M. Docosahexaenoic acid (DHA) incorporation into the brain from plasma, as an in vivo biomarker of brain DHA metabolism and neurotransmission. Prostaglandins Other Lipid Mediat. 2011;96:109–13.View ArticlePubMedPubMed CentralGoogle Scholar
  50. Harris WS, Lemke SL, Hansen SN, Goldstein DA, DiRienzo MA, Su H, Nemeth MA, Taylor ML, Ahmed G, George C. Stearidonic acid-enriched soybean oil increased the omega-3 index, an emerging cardiovascular risk marker. Lipids. 2008;43:805–11.View ArticlePubMedGoogle Scholar
  51. Lamaziere A, Richard D, Barbe U, Kefi K, Bausero P, Wolf C, Visioli F. Differential distribution of DHA-phospholipids in rat brain after feeding: A lipidomic approach. Prostaglandins Leukot Essent Fatty Acids. 2011;84:7–11.View ArticlePubMedGoogle Scholar
  52. Igarashi M, Ma K, Gao F, Kim HW, Greenstein D, Rapoport SI, Rao JS. Brain lipid concentrations in bipolar disorder. J Psychiatr Res. 2010;44:177–82.View ArticlePubMedGoogle Scholar
  53. Graf BA, Duchateau GS, Patterson AB, Mitchell ES, van Bruggen P, Koek JH, Melville S, Verkade HJ. Age dependent incorporation of 14C-DHA into rat brain and body tissues after dosing various 14C-DHA-esters. Prostaglandins Leukot Essent Fatty Acids. 2010;83:89–96.Google Scholar
  54. Kitson AP, Metherel AH, Chen CT, Domenichiello AF, Trépanier MO, Berger A, Bazinet RP. Effect of dietary docosahexaenoic acid (DHA) in phospholipids or triglycerides on brain DHA uptake and accretion. J Nutr Biochem. 2016;33:91–102.View ArticlePubMedGoogle Scholar
  55. Chen CT, Bazinet RP. β-oxidation and rapid metabolism, but not uptake regulate brain eicosapentaenoic acid levels. Prostaglandins Leukot Essent Fatty Acids. 2015;92:33–40.View ArticlePubMedGoogle Scholar
  56. Söderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids. 1991;26:421–5.View ArticlePubMedGoogle Scholar
  57. Eskelinen MH, Ngandu T, Helkala EL, Tuomilehto J, Nissinen A, Soininen H, Kivipelto M. Fat intake at midlife and cognitive impairment later in life: a population-based CAIDE study. Int J Geriatr Psychiatry. 2008;23:741–7.View ArticlePubMedGoogle Scholar
  58. Devore EE, Grodstein F, van Rooij FJ, Hofman A, Rosner B, Stampfer MJ, Witteman JC, Breteler MM. Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. Am J Clin Nutr. 2009;90:170–6.View ArticlePubMedPubMed CentralGoogle Scholar
  59. Cunnane SC, Schneider JA, Tangney C, Tremblay-Mercier J, Fortier M, Bennett DA, Morris MC. Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis. 2012;29:691–7.PubMedPubMed CentralGoogle Scholar
  60. Guesnet P, Alessandri J-M. Docosahexaenoic acid (DHA) and the developing central nervous system (CNS) – implications for dietary recommendations. Biochimie. 2011;93:7–12.View ArticlePubMedGoogle Scholar
  61. Park Y, Moon HJ, Kim SH. n-3 polyunsaturated fatty acid consumption produces neurobiological effects associated with prevention of depression in rats after the forced swimming test. J Nutr Biochem. 2012;23:924–8.View ArticlePubMedGoogle Scholar
  62. Mozaffarian D, Wu JH. (n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary? J Nutr. 2012;142:614S–25.View ArticlePubMedPubMed CentralGoogle Scholar
  63. Giles GE, Mahoney CR, Urry HL, Brunyé TT, Taylor HA, Kanarek RB. Omega-3 fatty acids and stress-induced changes to mood and cognition in healthy individuals. Pharmacol Biochem Behav. 2015;132:10–9.View ArticlePubMedGoogle Scholar
  64. Heinrichs SC. Dietary omega-3 fatty acid supplementation for optimizing neuronal structure and function. Mol Nutr Food Res. 2010;54:447–56.View ArticlePubMedGoogle Scholar
  65. Pusceddu MM, Kelly P, Stanton C, Cryan JF, Dinan TG. n-3 polyunsaturated fatty acids through the lifespan: implication for psychopathology. Int J Neuropsychopharmacol. 2016;19:pii: pyw078.Google Scholar
  66. Husted KS, Bouzinova EV. The importance of n-6/n-3 fatty acids ratio in the major depressive disorder. Medicina. 2016;52:139–47.View ArticlePubMedGoogle Scholar
  67. Morgese MG, Trabace L. Maternal malnutrition in the etiopathogenesis of psychiatric diseases: role of polyunsaturated fatty acids. Brain Sci. 2016;6:pii: E24.Google Scholar
  68. Levant B, Ozias MK, Davis PF, Winter M, Russell KL, Carlson SE, Reed GA, McCarson KE. Decreased brain docosahexaenoic acid content produces neurobiological effects associated with depression: interactions with reproductive status in female rats. Psychoneuroendocrinol. 2008;33:1279–92.View ArticleGoogle Scholar
  69. Wu A, Ying Z, Gomez-Pinilla F. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J Neurotrauma. 2004;21:1457–67.View ArticlePubMedGoogle Scholar
  70. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000;71:343S–8S.PubMedGoogle Scholar
  71. Simopoulos AP. An increase in the omega-6/omega-3 fatty acid ratio increases the risk for obesity. Nutrients. 2016;8:128.View ArticlePubMedPubMed CentralGoogle Scholar
  72. Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME. Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron. 1998;20:709–26.View ArticlePubMedGoogle Scholar
  73. Aid T, Kazantseva A, Piirsoo M, Palm K, Timmusk T. Mouse and rat BDNF gene structure and expression revisited. J Neurosci Res. 2007;85:525–35.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement